AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02525003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Experimental group 2: daily vitamin D2 supplement 25ug/d for 8 weeks
Study NCT02525003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Experimental group 3: daily vitamin D3 supplement 25ug/d for 8 weeks
Study NCT02525003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D2 fortified bread
Description: Experimental group 4: vitamin D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
Study NCT03745222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: PD-1 inhibitor (monoclonal antibody against PD-1)
Study NCT03745222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (cCRT)
Description: Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.
Study NCT03745222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Concurrent chemoradiotherapy (cCRT)
Description: Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.
Study NCT03745222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03745222 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03074214 — intervention group
Intervention type: PROCEDURE
Intervention: percutaneous coronary intervention
Description: All STEMI patients enrolled will at first receive Device(such as: stent or balloon) treatment for their coronary artery.
Study NCT01201811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
Study NCT02737085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells
Description: Patients receive autologous-derived CD19-targeted CAR-T cells following CD20-targeted CAR-T cells after receiving lymphodepleting chemotherapy.
Study NCT04284397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ASA
Description: A sub-group of older adults will be re-tested after 7 days of treatment with low-dose aspirin.
Study NCT04284397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: All participants will be tested with no treatment.
Study NCT02796430 — intervention group
Intervention type: OTHER
Intervention: Time needed to start indirect calorimetry measurement
Description: Comparison of the time needed to start EE measurements by the new calorimeter and the currently used calorimeter, including the time needed for calibration, patient data input, connection to the ventilator circuit.
Study NCT02796430 — intervention group
Intervention type: OTHER
Intervention: Indirect calorimetry measurement
Description: Comparison of EE measurements by the new calorimeter and the currently used calorimeter when using different mechanical ventilators, different ventilation modes, different patient conditions and severity
Study NCT02707458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike statin drugs used widely in Canada and the US.
Study NCT03842410 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Single-Incision Sling
Description: Solyx Single-Incision Sling for correction of stress urinary incontinence done in the office.
Study NCT01677702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml)
Description: Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
Study NCT00574353 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission
Description: You will be scanned 2 to 3 times on the same day, but you will only be administered one dose of the FMISO tracer. The first scan will last about 30 minutes. Then you will have 1 to 3 hours to wait before you are scanned again. Some patients will undergo a second scan approximately one-and-a-half hours after the start of the first scan. This scan will last about 10 minutes. The final scan will occur between 2-4 hours after the start of the first scan. This final scan will also last about 10 minutes. During the PET scan, you may have a separate i.v. line put into your other arm so that we can take 2 to 3 blood samples. These samples will be less than half a teaspoon each. We are taking these blood samples to see how quickly FMISO leaves your blood stream. The first sample will be taken between 2 and 40 minutes after the FMISO is injected. The other two blood samples will be taken with each subsequent scan.
Study NCT02844842 — intervention group
Intervention type: BIOLOGICAL
Intervention: Allergovac Poliplus
Study NCT02309411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
Study NCT01677702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml)
Description: Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
Study NCT01677702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Recombined low protein milk
Description: Total 250ml of placebo milk will be taken once a day at 10am daily during the 84 day intervention.
Study NCT02387892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cheese & yogurt + Vitamin D
Description: cheese \& yogurt with added 420 IU cholecalciferol
Study NCT02387892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cheese & yogurt
Description: Cheese \& yogurt without added vitamin D
Study NCT00259922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00259922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Description: 0.5 mg QD
Study NCT00259922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alviompan
Description: 0.5 mg BID
Study NCT03960671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam/diazepam/propofol
Description: Therapeutic drug monitoring of anxiolytics
Study NCT01109823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous administration of levofloxacin
Description: Intravenous administration of levofloxacin is used.
Study NCT03060174 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: monitoring and non-medical prophylaxis of delirium
Study NCT01167114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Description: Given intravenously on Day 1, 8 and 15 of each 4 week cycle.
Study NCT00177840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Study NCT00177840 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Study NCT02640404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular. 2 doses 3 months apart
Study NCT02640404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular.
Study NCT02149758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Study NCT02149758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoricoxib
Study NCT01946958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in PC Triple P
Description: PC Triple P is a brief parenting intervention combining specific advice from provider with parent rehearsal and self-evaluation.
Study NCT02986607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parathyroid hormon 1-84
Description: Hypoparathyroidism patients will receive Natpara in continous subcutaneous infusion delivered by a pump for 4-7 days.
Study NCT02209012 — intervention group
Intervention type: DRUG
Intervention: Aminolevulinic Acid (ALA)
Description: Levulan PDT given in CP0108
Study NCT02209012 — intervention group
Intervention type: DRUG
Intervention: Topical Solution Vehicle
Description: Vehicle PDT given in CP0108
Study NCT02209012 — intervention group
Intervention type: DEVICE
Intervention: BLU-U Blue Light Photodynamic Therapy Illuminator
Description: PDT given in CP0108
Study NCT01960647 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous transluminal angioplasty with uncoated balloon
Study NCT01960647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transluminal angioplasty with Paclitaxel balloon
Study NCT00499863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate transdermal system
Description: dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
Study NCT00499863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch
Study NCT01946958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care As Usual
Description: Pediatric residents not exposed to PC Triple P provide their standard care to parents struggling with parenting issues or child behavior concerns.
Study NCT02666196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAA-I
Study NCT04299516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-team simultaneous bilateral total knee arthroplasty
Description: Bilateral total knee arthroplasty can be performed in three different ways: single-stage, two-team simultaneous bilateral total knee arthroplasty; single-stage, one-surgeon, and two-stage bilateral total knee arthroplasty. Two surgeons will operate simultaneously on one side for two-team SBA.
Study NCT04299516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-team simultaneous bilateral total knee arthroplasty
Description: One surgeon will operate sequentially on both sides for one-surgeon SBA
Study NCT02535364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR015 (CD19-targeted CAR T cells)
Description: Part A: Following leukapheresis and concurrent with generation of JCAR015, participants received, at the Investigator's discretion, cytoreductive chemotherapy based on the Investigator's choice of regimens and/or supportive care.~Part B: Participants who were eligible for treatment in Part B received two IV doses of JCAR015 CAR T cells separated by 14 to 28 days. JCAR015 infusion was preceded by lymphodepleting chemotherapy with cyclophosphamide alone or cyclophosphamide + fludarabine.
Study NCT04792125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External electrical stimulation (EES) added to pelvic floor muscle training (PFMT)
Description: Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.~While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week.
Study NCT04792125 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: External electrical stimulation
Description: Patients will be treated with the Innovo device using eight external electrodes with a combined stimulator. Electrodes will be applied to the buttocks, outer hips and anterior and posterior proximal thighs 3 days a week for 30 minutes each session.
Study NCT04792125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Description: While explaining the exercise to the patients, it was stated that 1 set of exercise consisted of 10 fast contractions and 10 slow contractions. For the first 2 weeks, they were asked to exercise 2 sets a day, every day. Thus, in the first 2 weeks, 20 fast contractions and 20 slow contractions were performed. Then, 2 sets were increased every two weeks and the exercise was ended as 8 sets (80 fast and 80 slow contractions) at the end of the 8th week.
Study NCT02661100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg/kg by IV infusion on Day 1 of each 3 week cycle. Given until disease progression
Study NCT02661100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-1401
Description: 1mg given subcutaneously on day 1 of each 3 week cycle. Given for 4 cycles
Study NCT02661100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: 2mg given subcutaneously on day 1 and 2 of each 3 week cycle. Given for 4 cycles
Study NCT02138643 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic surgery
Description: These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
Study NCT02138643 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic surgery
Description: These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
Study NCT02634788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine sublingual spray delivered via single 100 μL spray
Study NCT02634788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
Study NCT02452086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser(Ga-As)
Description: Low level laser therapy(904 nm Wavelength), 90 milliwatt, 2 Joule/centimeter2
Study NCT02452086 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: LLLT with zero intensity
Study NCT02464683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VitaminD
Description: 200 International Units (oral dose) daily of 60 days
Study NCT03737786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tight control of end-tidal CO2 levels
Description: The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation
Study NCT02666196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03173690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reconciliation at the ICU
Description: Medication reconciliation performed according to Integrated Medicines Management model
Study NCT03173690 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medication Reconciliation at the Ward
Description: Medication reconciliation performed according to Integrated Medicines Management model
Study NCT03173690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Reconciliation at the Ward
Description: Medication reconciliation performed according to Integrated Medicines Management model
Study NCT03466203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LLF580
Description: LLF580 300mg
Study NCT03466203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to LLF580
Study NCT01864369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eCounseling + Usual Care
Description: This intervention will use film vignettes and interactive web pages. The e-counseling messages will promote: (i) validation of the subject's stage of readiness for behavior change, (ii) collaborative participation by means of subject-selected menus, (iii) reinforcement of change talk to resolve ambivalence, (iv) use of self-help information and e-tools for self-monitoring of targeted self-care behaviors, and (v) development of cognitive-behavioral skills to build and strengthen efficacy. Messages will be proactively sent to Controls according to the following schedule: weekly for months 1 to 4, bi-weekly for months 5 to 8, and monthly for months 9 to 12.
Study NCT01864369 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eCounseling + Usual Care
Description: This intervention will use film vignettes and interactive web pages. The e-counseling messages will promote: (i) validation of the subject's stage of readiness for behavior change, (ii) collaborative participation by means of subject-selected menus, (iii) reinforcement of change talk to resolve ambivalence, (iv) use of self-help information and e-tools for self-monitoring of targeted self-care behaviors, and (v) development of cognitive-behavioral skills to build and strengthen efficacy. Messages will be proactively sent to Controls according to the following schedule: weekly for months 1 to 4, bi-weekly for months 5 to 8, and monthly for months 9 to 12.
Study NCT00998075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole/ASA Fixed Combination
Description: Capsule, oral, single dose
Study NCT00998075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole - Nexium
Description: Clinical Trial Capsule or MUPS Tablet, oral, single dose
Study NCT01846000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-level laser treatment
Description: A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.
Study NCT01846000 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: low-level laser treatment
Description: A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.
Study NCT01452646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk-adapted, MRD-directed therapy
Description: The general objective of this study is that of setting up a multicentre, risk-adapted study that relies on pre-treatment cytogenetic/genetic features and post-consolidation assessment of MRD to establish the final risk assignment and treatment of younger (≤ 60 years) patients with AML. Aim of this clinical trial is to verify whether the delivery of a post remission therapy whose intensity is risk-driven will improve the outcome in terms of both increased anti-leukemic efficacy and reduced therapy-related toxicity.
Study NCT02293746 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Inspire® Upper Airway Stimulation (UAS) System
Description: This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.
Study NCT03234153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Imfinzi)
Description: Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
Study NCT03234153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 75 mg i.v. in combination with Durvalumab 1500 mg i.v. every 4 weeks every 4 weeks for a total of 4 cycles before surgery.
Study NCT02223884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel 35mg/m2
Description: D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
Study NCT02223884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC3
Description: D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
Study NCT01965782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-LY3023703
Description: Administered orally
Study NCT03249610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Intervention Trial with Multi-Component Lifestyle Intervention for reduction of body weight and cardio-metabolic risk factors